Supplementary material - Supplemental material for Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers

<p>Supplemental material, Supplementary material for Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers by Jan de Hoon, Anne Van Hecken, Corinne Vandermeulen, Marissa Herbots, Yumi Kubo, Ed Lee, Osa Eisele, Gabriel Vargas and Kristin Gabriel in Cephalalgia</p

Booster response to 30 μg adjuvanted clade 2/ Indonesia/5/05-RG2 vaccine at 22 months following the first vaccination.

<p>Booster response to 30 μg adjuvanted clade 2/ Indonesia/5/05-RG2 vaccine at 22 months following the first vaccination.</p

Antibody persistence as defined by HI antibody titer at 6/15/22-months following the first vaccination with clade 1 A/Vietnam/1194/2004/NIBERG-14.

<p>Antibody persistence as defined by HI antibody titer at 6/15/22-months following the first vaccination with clade 1 A/Vietnam/1194/2004/NIBERG-14.</p

Solicited adverse events following booster vaccination or in case of clade 2 primary vaccination within 3 to 7-days after vaccination.

<p>Solicited adverse events following booster vaccination or in case of clade 2 primary vaccination within 3 to 7-days after vaccination.</p

21 Day Booster response to 7.5 μg clade 1 A/Vietnam/1194/2004/NIBERG-14 6-months after the first vaccination.

<p>21 Day Booster response to 7.5 μg clade 1 A/Vietnam/1194/2004/NIBERG-14 6-months after the first vaccination.</p

Primary response following clade 2 A/Indonesia /5/05-RG2 as determined by HIH method.

<p>Primary response following clade 2 A/Indonesia /5/05-RG2 as determined by HIH method.</p